Glycosylated haemoglobin in chronic renal failure and after renal transplantation

D FREEDMAN, P DANDONA, O FERNANDO, JF MOORHEAD

From the Metabolic Unit, Department of Chemical Pathology, and the Department of Nephrology and Transplantation, Royal Free Hospital, Pond Street, London NW3 2QG

SUMMARY Haemoglobin A₁ (HbA₁) was determined by ion-exchange chromatography in 37 normoglycaemic patients with chronic renal failure (CRF) and 26 with successful renal transplants. Blood glucose concentrations in patients with CRF were similar to those in controls, and there was a significant correlation between fasting blood glucose concentration and HbA₁ in these groups. HbA₁ in patients with CRF was, however, significantly lower than that in control subjects. Concentrations of HbA₁ in patients on haemodialysis, peritoneal dialysis, and those with steady state CRF prior to dialysis were not significantly different from each other. Whereas patients with successful renal transplants of greater than 3 months' duration had HbA₁ concentrations indistinguishable from controls, HbA₁ in patients with transplants of shorter duration were significantly lower. These observations are suggestive of a shortened erythrocyte survival in CRF per se. Furthermore, these results indicate: (a) the inadequacy of HbA₁ in monitoring the quality of diabetic control in patients with CRF, and (b) the absence of a specific effect of dialysis on HbA₁, and the restoration to normal of HbA₁ after successful renal transplantation.

Haemoglobin A₁ (HbA₁) has previously been shown in a preliminary study to be significantly lower in patients with CRF than in controls.¹ Since the HbA₁ content of any erythrocyte is dependent on the duration of glycosylation—that is, life span of the erythrocyte and the rate of glycosylation—that is, the concentration of plasma glucose,² it follows that a diminution of HbA₁ in euglycaemic patients is suggestive of shortened erythrocyte survival. Previous studies using ⁵¹Cr-labelled red blood cells (RBC) have also shown a shortened erythrocyte survival in patients with CRF.³

We have now attempted to answer the questions (i) whether the low HbA₁ and shortened survival of erythrocytes are secondary to CRF per se or to long term haemodialysis; (ii) whether HbA₁, in peritoneally dialysed and haemodialysed patients are significantly different and (iii) whether successful transplantation restores HbA₁ to normal.

Patients and methods

The following groups of patients were studied:

Group 1 Patients (n = 8) with low creatinine clearance (Cr cl < 20 ml/min) on dietary restriction but no dialysis treatment (mean plasma glucose = 4.4 mmol/l).

Group 2 Patients (n = 10) with CRF (Cr cl < 10 ml/min) on peritoneal dialysis for duration of more than 1 month (mean plasma glucose = 4.6 mmol/l).

Group 3 Patients (n = 19) with CRF (age range 10 to 53 years, mean 34 years) on long-term haemodialysis for duration of more than 2 months (mean plasma glucose = 4.0 mmol/l).

Group 4 Patients (n = 6) with recent renal transplants less than 3 months' duration (Cr cl 10 to 53 ml/min) (mean plasma glucose = 4.5 mmol/l).

Group 5 Patients (n = 20) with successful renal transplants greater than 3 months' duration (Cr cl 25 to 120 ml/min) (mean plasma glucose = 3.9 mmol/l).

Group 6 Control group (n = 17) (mean plasma glucose 4.2 mmol/l).

None of these patients had fasting or post prandial hypoglycaemia, hyperglycaemia, glycosuria or hypoglycaemia.

Blood samples were collected in heparin and were stored in a refrigerator at 4°C before HbA₁ measurement. All estimations were carried out within three days of collection of the sample. Haemoglobin A₁ was measured by a kit (Isolab Laboratories) with
chromatographic separation of HbA1c from HbA1 on a biorex microcolumn at constant temperatures of 22.5°C in an incubator. All HbA1c results were expressed as percentage of total haemoglobin and not absolute concentrations.

Results

HbA1c% in patients with CRF prior to dialysis was 5.8 ± 0.7 (mean ± SD); this was significantly lower than that in controls (mean ± SD = 7.3 ± 0.7%; p < 0.001) although the mean blood glucose in two groups was similar (4.4 mmol/l v 4.2 mmol/l) (Fig. 1). HbA1c% in patients on haemodialysis (mean ± SD = 5.3 ± 0.4) and peritoneal dialysis (mean ± SD = 5.7 ± 0.7) was not significantly different from that in patients with CRF prior to dialysis. There was no significant difference in HbA1c% between the two dialysis groups.

In patients with transplants of less than 3 months’ duration HbA1c% (mean ± SD = 5.7 ± 0.7) was similar to that in patients with CRF and was significantly lower than that in controls (p < 0.01). HbA1c% in patients with successful renal transplants of longer duration (mean ± SD = 6.8 ± 1.0) was significantly greater than that in patients with CRF (p < 0.01) and those with recent transplants (p < 0.01); it was not significantly different from that in controls. There was a significant correlation between blood glucose concentration and HbA1c% in patients on haemodialysis (r = 0.8), those with long term transplants (r = 0.8) and in controls (r = 0.65) (Fig. 2). Patients on long-term haemodialysis had lower HbA1c% for a given blood glucose concentration that when compared with normal subjects and there was no overlap between the two groups (p < 0.05, Student’s unpaired t test).
Discussion

It is clear from our observations that CRF is associated with markedly lower HbA1c% without a concomitant change in blood glucose concentrations. Successful renal transplantation in the long term restores HbA1c% to concentrations similar to those observed in normal subjects. It is of interest that in our series blood glucose concentrations in various patient groups were not significantly different from controls. This allows us to make valid comparisons of HbA1c% in different groups.

Thus, the restoration of normal HbA1c% in transplanted patients does not appear to be the consequence of steroid therapy. Indeed, this normalisation of HbA1c% occurs at a stage when the dose of steroids is relatively low. The reason why it takes approximately three months for the normalisation of HbA1c to occur is probably due to the time taken for pretransplantation RBCs with low HbA1c to be replaced by a new population of RBCs with a normal survival and hence a normal HbA1c content.

Apart from indicating that HbA1c% would be an unreliable index of glucose homeostasis in patients with advanced diabetic nephropathy or CRF due to any other cause, our observations have interesting haematological implications.

The diminished HbA1c% in uraemic patients without an alteration in blood glucose concentrations is consistent with a shortened RBC survival in these patients. However, it is surprising that HbA1c% in patients on haemodialysis was not significantly different either from that in uraemic patients prior to dialysis or that in patients on peritoneal dialysis. This suggests that the main cause of shortened RBC survival in patients with CRF is uraemia and not haemodialysis.

In conclusion, CRF is associated with a reduction of HbA1c irrespective of dialysis treatment or its mode. This reduction in HbA1c is restored to normal after successful renal transplantation. These observations may have important implications in terms of erythrocyte survival and the assessment of glycaemic control in CRF.

The authors wish to thank Mrs M Elleman for secretarial assistance.

References


Requests for reprints to: Dr P Dandona, Metabolic Unit, Department of Chemical Pathology, Royal Free Hospital, London NW3 2QG, England.
Glycosylated haemoglobin in chronic renal failure and after renal transplantation.

D Freedman, P Dandona, O Fernando and J F Moorhead

_J Clin Pathol_ 1982 35: 737-739
doi: 10.1136/jcp.35.7.737

Updated information and services can be found at:
http://jcp.bmj.com/content/35/7/737

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/